Shares of Alnylam Pharmaceuticals(NASDAQ: ALNY) have dropped 24% so far this year (through June 30). The biotech company is still a darling of Wall Street analysts, with 14 of 29 analysts following it listing the stock as a buy and seven listing it as a strong buy as I write this. The average price target is $436, about 45% above the June 30 closing price.
Since 2018, the company has brought to market six RNA interference (RNAi) therapeutics, genetic medicines that use RNA interference to inhibit specific disease-associated genes. Here's why things are looking good for the stock, and one note of caution.
Capital Daily covers markets, crypto and commodities for Asia & the Middle East — tier-1 desk research, AI-driven analysis, institutional-grade data. Tip our newsroom: [email protected]
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.
What moved overnight · what to watch today · pre-positioning notes from our desk. Delivered to your inbox at 6:30 AM Dubai.
No spam. Unsubscribe in one click. We never sell your email.
We use cookies and similar technologies to improve your experience, serve personalized ads, and analyze traffic. You can manage your preferences or accept/reject all.
Cookie Preferences
EssentialRequired for the site to function. Always active.
AnalyticsHelp us understand how visitors interact with the site.
AdvertisingUsed to deliver personalized ads.
FunctionalEnable enhanced functionality and personalization.
